Scope
* Detailed analysis of the financial benefits and risks related to the adoption of Omontys at dialysis centers
* Discussion of the company's strategy, commercial relationships, and forthcoming catalysts
* Sales forecasts through to 2017
* Financial analysis of the company, including operating performance forecasts through to 2017
Highlights
This report contains patient-based forecasts for Affymax's Omontys, a once monthly erythropoiesis-
------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/
------------------------------------------------------------
Reasons to Get this Report
* Analyze how the performance of Omontys will shape Affymax's growth prospects
* Assess the current ESA market in the dialysis setting and how various factors are forecast to affect Omontys sales
* See how Affymax's development and marketing relationship with Takeda will contribute to the company's overall strategic outlook
Report Table of Contents:
ABOUT THIS REPORT
* PharmaVitae Explorer database
* Chapter structure
* Sales and product analysis
* Financial analysis
* Data sourcing
* Analyst consensus
* Primary research
EXECUTIVE SUMMARY
* Company introduction
* Recent developments
* Corporate relationships
* Strategic overview
* SWOT analysis
* Strengths
* Weaknesses
* Opportunities
* Threats
SALES AND PRODUCT ANALYSIS
* Sales overview
* Product analysis
* Product sales
* Omontys (peginesatide)
* Chronic kidney disease background
* Dialysis background
* Omontys clinical trials in ESRD and CKD
* EMERALD trials in dialysis patients
* PEARL trials in non-dialysis patients
* Ongoing DIAMOND and PRCA trials
* Factors affecting the use of Omontys
* Omontys is only cheaper than Epogen at higher doses
* Omontys's once-monthly dosing is a double-edged sword
* Many centers will be reluctant to stock two different ESAs for in-center use
* Home dialysis patients should see the quickest uptake of Omontys
* Lack of Omontys-associated PRCA expected to have minimal impact on adoption
* Pricing negotiations with group purchasing organizations and small dialysis centers will be key to Omontys uptake
* Mircera is another once-monthly ESA on the horizon
FINANCIAL ANALYSIS
* Financial performance overview
* Operating costs and profit analysis, 2005-11
* Operating costs and profit analysis, 2011-17
APPENDIX
* Primary research
* References
* Exchange rates
TABLES
* Table: Affymax: key catalysts
* Table: Affymax product portfolio overview ($m), 2011-17
* Table: Overview of pivotal trial data for Omontys, EMARALD 1 and 2 studies
* Table: ESA price comparison, by equivalent dosage
* Table: Omontys US forecast model, 2012-17
* Table: Affymax operating revenue/cost analysis ($m), 2005-11
* Table: Affymax operating revenue/cost analysis ($m), 2011-17
* Table: Exchange rates, 2011
FIGURES
* Figure: PharmaVitae Explorer
* Figure: Affymax prescription pharmaceutical performance, sales ($m) and growth rate (%), 2011-17
* Figure: Affymax product sales ($m), 2011-17
* Figure: Weekly Epogen dose among large and medium sized dialysis organizations, August 2010-December 2011
* Figure: Weekly Epogen dose among small and independent dialysis organizations, August 2010-December 2011
* Figure: Price of Omontys relative to Epogen dose equivalent
* Figure: Price of Omontys relative to Aranesp dose equivalent
* Figure: Affymax operating/cost performance ($m), 2005-17
About Datamonitor
The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.
